Earnings Feed
Start Free
Home/Filings/4/0001493152-24-042953
4//SEC Filing

Forman Stephen J. 4

Accession 0001493152-24-042953

CIK 0001335105other
View on SEC.govCompany Profile

Filed

Oct 28, 8:00 PM ET

Accepted

Oct 29, 5:42 PM ET

Size

18.1 KB

Accession

0001493152-24-042953

Insider Transaction Report

Form 4
Period: 2024-09-30
LIXTE BIOTECHNOLOGY HOLDINGS, INC.LIXT
Forman Stephen J.
Director
Transactions
  • Award

    Options to Purchase Common Stock

    2024-09-30+3,858→ 3,858 total
    Exercise: $1.30From: 2024-09-30Exp: 2029-09-30→ Common (3,858 underlying)
Holdings

  • Options to Purchase Common Stock

    Exercise: $7.45From: 2022-06-30Exp: 2027-06-30→ Common (10,000 underlying)
    10,000

  • Options to Purchase Common Stock

    Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (10,000 underlying)
    10,000

  • Options to Purchase Common Stock

    Exercise: $5.88From: 2023-06-30Exp: 2028-06-30→ Common (10,000 underlying)
    10,000

  • Options to Purchase Common Stock

    Exercise: $30.30From: 2021-06-30Exp: 2026-06-30→ Common (10,000 underlying)
    10,000

  • Options to Purchase Common Stock

    Exercise: $9.00From: 2017-10-16Exp: 2022-10-16→ Common (833 underlying)
    833

  • Options to Purchase Common Stock

    Exercise: $66.00From: 2019-05-22Exp: 2024-05-22→ Common (833 underlying)
    833

  • Options to Purchase Common Stock

    Exercise: $2.37From: 2024-06-30Exp: 2029-06-30→ Common (3,018 underlying)
    3,018

  • Warrants to Purchase Common Stock

    (indirect: By Trust)
    Exercise: $60.00From: 2018-12-07Exp: 2022-12-07→ Common (1,667 underlying)
    1,667

  • Options to Purchase Common Stock

    Exercise: $32.10From: 2021-01-06Exp: 2026-01-06→ Common (5,000 underlying)
    5,000

  • Warrants to Purchase Common Stock

    (indirect: By Trust)
    Exercise: $57.00From: 2018-12-07Exp: 2022-12-07→ Common (2,105 underlying)
    2,105
Footnotes (1)
  • [F1]Effective September 30, 2024, the reporting person was granted stock options to purchase an aggregate of 3,858 shares vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.

Documents

1 file

Issuer

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

CIK 0001335105

→
Entity typeother

Related Parties

1
  • filerCIK 0001676461

Filing Metadata

Form type
4
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 5:42 PM ET
Size
18.1 KB
View on SEC.gov